Análise dos custos do procedimento PET-TC com 18 F-FDG na perspectiva do SUS provedor: estudo em uma unidade pública de saúde do Rio de Janeiro, Brasil

Abstract

Positron emission tomography (PET) has been introduced recently in Brazil and requires costs analysis to support economic evaluation studies on its use. The current study analyzed the use of 18 F-FDG PET-CT and estimated its costs from the perspective of a public healthcare provider. The micro-costing technique was used, identifying, quantifying, and valuing all the inputs used to perform the procedure. Cost estimates considered 85 tests performed at the Brazilian National Cancer Institute from March to June 2012. Reference cases were defined as adult cancer patients, output of five tests per day, and one dose of 18 F-FDG per patient. Unit cost for the procedure was BRL 3,150.30 based on career wages under the Ministry of Science and Technology and BRL 2,927.19 based on Ministry of Health career wages. The factor with the heaviest cost impact was daily output of tests. Other factors that could impact the test's cost in public healthcare institutions were also examined.

Budget impact from the incorporation of positron emission tomography – computed tomography for staging lung cancers

“…As the PET-CT procedure was not included in SUS payrolls when the analyses were conducted, we used values as estimated by micro-costing. 3 The values were calculated again to have a 30.0% reduction in the F18-fluoro-2-deoxy-D-glucose costs ( 18 FDG), h to consider the recent increase in the number of private input producers which took place when the Federal Government lost its monopoly for radiopharmaceuticals in 2006. For all procedures figuring in SUS payroll charts, values regarding November 2013 were used, which were listed in SUS Management System for the Chart of Procedures, Medications, and Orthoses, Prosthetics, and Special Materials.…”

“…Como o procedimento PET-TC não se encontrava incorporado às tabelas de pagamento do SUS quando da realização das análises, utilizaram-se valores estimados por microcustos. 3 Os valores foram recalculados com redução de 30,0% nos custos do F 18 -fluoro-2-desoxi-D-glicose ( 18 FDG) h para contemplar a recente expansão dos produtores privados do insumo advinda da queda do monopólio da União na produção de radiofármacos em 2006. Para todos os procedimentos presentes nas tabelas do SUS, foram utilizados valores de novembro de 2013, presentes no Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e Órteses, Próteses e Materiais Especiais do SUS.…”

Highlighting COVID-19: What the imaging exams show about the disease

“…The 18 F-FDG PET/CT exam has important disadvantages. The test is still expensive and inaccessible for some people, especially those living in poor countries[ 77 ]. In addition, the low physical half-life, approximately 110 min, of 18 F-FDG is a problem, because this limitation prevents the examination from being carried out in places distant from the producers of this tracer[ 78 ].…”

Custo-efetividade do uso da tomografia de emissão de pósitrons na detecção de recorrência do câncer diferenciado de tireoide

“…Valores dos procedimentos diagnósticos e terapêuticos presentes nas tabelas de pagamento do SUS foram obtidos do Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS (SIGTAP), considerando vigência de junho/2013 (tabela 1). Os custos dos procedimentos de PET-TC, ainda não presentes nas tabelas de pagamento do SUS, foram estimados em estudo anterior pela técnica de microcustos, tomando por base a perspectiva de um provedor público de saúde e tendo o Instituto Nacional do Câncer (INCA) como lócus de estudo (CAETANO et al, 2014).…”